Australia Health

Monash IVF (ASX:MVF) has appointed Matt Harrington as CFO, with his start date set for Jan. 4, 2027.

Clarity Pharmaceuticals (ASX:CU6) completed recruitment for the main group of its Phase 1/2a SECuRE trial evaluating 16 patients with metastatic castration-resistant prostate cancer.

NOVONIX (ASX:NVX) has achieved ISO 9001:2015 certification following an independent audit of its quality management system.

Telix Pharmaceuticals (ASX:TLX) announced that the first set of patients in the United States received commercial doses of its newly approved brain cancer imaging drug.

Cyclopharm (ASX:CYC) announced that seven Chinese medical bodies published an expert consensus naming Technegas as the preferred lung ventilation imaging agent.

AFT Pharmaceuticals (ASX:AFP) announced sustained double-digit revenue growth for the first half of FY27.

Aroa Biosurgery (ASX:ARX) released clinical trial results showing its Symphony biosaffold improved healing outcomes for patients with diabetic foot ulcers.

Dimerix (ASX:DXB) announced that its first patient completed a two-year open-label extension study, marking four continuous years of DMX-200 treatment.

Imugene (ASX:IMU) released clinical results showing a 71% overall response rate in seven evaluable patients enrolled in Cohort 3 of its azer-cel Phase 1b trial.

HealthCo Healthcare & Wellness REIT (ASX:HCW) has secured binding lease agreements for its 10 Healthscope hospitals.

CSL (ASX:CSL) signed an agreement with Alentis Therapeutics to co-develop and co-promote lixudebart in an upfront deal worth US$355 million.

Artrya (ASX:AYA) executed a five-year commercial agreement with Huntsville Hospital Health System featuring a minimum contracted value of US$0.5 million.